Chugai Pharmaceutical stock
4519.TJPXChugai Pharmaceutical Co., Ltd., HealthcareISIN JP3519400000
78Score 78 out of 100, Strong
Price and trend
58 / 100
Price history
−8.9% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 7.7% below it.
Since June 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 64).
The price is 32% below its 52-week high. Largest decline in 20 years: 66% (February 2007 to March 2008).
Chart figures for advanced users
- SMA 50$41.29
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$48.61
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)64
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$37.80
- The lowest closing price of the last twelve months.
- Resistance$65.66
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Chugai Pharmaceutical Co., Ltd. belongs to the Drug Manufacturers (General) industry (Japan) and, with a market value of $73.87B, is number 15 of 27 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $7.9B (up 7.5% year on year) and earnings of $2.73B (up 12.1%).
- For fiscal 2026, analysts expect on average revenue of $8.69B (up 10.1%) and adjusted earnings per share of $1.93 (up 12.8%).
Show more
- MEQIRI Score 78 out of 100 (Strong): rank 31 of 714 in Healthcare, median 53.
- The P/E is 23.4 (Drug Manufacturers (General) median 17.3, own median of recent years 32.7).
- Our model puts fair value at $47.84, with the price 6% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 43.7% in fiscal 2025, Healthcare sector median 9.1%.Profitability 97
- High marginNet margin 35.6% over the last 12 months, Healthcare sector median 13.8%.Profitability 97
- Reliable dividendNo dividend cut for over 26 years.Capital allocation 77
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are profitability and fundamentals.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $34.17 and expensive above $79.74 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $62.37 (cash-flow model) and $33.31 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 6.1%. At 7.1% the fair value would be $42.19, at 5.1% it would be $56.37.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (17.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 16.5% on the twelve months before. Revenue has grown solidly since 2006, at about 7% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 71%, operating 47%, net 35%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 4 Feb 2027in 84 days
- Last reported
- 27 Oct 2026EPS reported $0.58 (expected $0.48)above expectations
Analyst estimates
Earnings estimates have barely changed since 26 Oct 2026.
- Earnings per share
- $1.93+0.3%
- Revenue
- $8.69B+0.3%
- Earnings per share
- $2.21+0.1%
- Revenue
- $9.51B+0.3%
MEQIRI has stored the estimates since 26 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −3.6%Chugai expects to exceed its full year revenue and profit forecast, with Actemra sales seen coming in more than 10 billion yen above plan.
“So as to say, we expect the full year sales to actually exceed the forecast by about or more than JPY 10 billion.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 27 Oct 2026 (fiscal Q3 2026), read by AI.
What happened at Chugai Pharmaceutical
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 78
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next larger and next smaller companies by market value
- PfizerPFE $167.86B61
- Bristol-Myers SquibbBMY $128.59B71
- SanofiSAN.PA $115.46B67
- GSKGSK $101.43B70
- BayerBAYN.DE $62.05B53
- Otsuka Holdings4578.T $39.66B78
- BiogenBIIB $37.46B60
- Daiichi Sankyo4568.T $31.7B71
ETFs that hold Chugai Pharmaceutical
Held by 98 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| UBS MSCI Japan Climate Paris Aligned UCITS ETF ir-hEUR accAW1Q | 4.61% | 0.15% | €191.34M |
| L&G Pharma Breakthrough UCITS ETFETLI | 2.47% | 0.49% | €26.29M |
| iShares MSCI Japan CTB Enhanced ESG UCITS ETFEDMJ | 1.43% | 0.15% | €1.27B |
Show 5 more
| WisdomTree Japan Equity UCITS ETF USD HedgedWTDX | 1.30% | 0.48% | €796.64M |
| Xtrackers MSCI Japan ESG UCITS ETF 1CXZMJ | 1.22% | 0.20% | €2.69B |
| Xtrackers Nikkei 225 UCITS ETF 1DXDJP | 1.20% | 0.09% | €2.56B |
| Deka MSCI Japan Climate Change ESG UCITS ETFEL45 | 0.92% | 0.26% | €162.3M |
| Amundi MSCI Japan ESG Broad Transition UCITS ETF EUR AccJ1GR | 0.81% | 0.15% | €1.31B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = ¥159.23)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Jul 2019)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.